Bionexo announces Rafael Barbosa as the new CEO

São Paulo, January 31, 2019 – Bionexo, a Brazilian multinational company focused in digital technology for the healthcare sector, announces today Rafael Barbosa as the new CEO. Mr. Barbosa was appointed by the Board of Directors, replacing Rodrigo Borer, who, during the period in which he was at the helm of the company, contributed decisively to its strengthening.

Rafael Barbosa, who is 33 years old, joined Bionexo in 2015 as New Business Manager. Subsequently, he assumed the position of Director of Products. Mr Barbosa holds a degree in Economics from Universidade Federal de Santa Catarina, a master degree in Business Development from Unicamp and an MBA from the Darden School of Business, in the University of Virginia. He began his career as a project consultant for World Bank projects in the Brazilian Amazon. There, he was responsible for the execution and monitoring of public politics regarding primary healthcare and social development.

In the private sector, Rafael Barbosa worked at Bessemer Venture Partners, an American Venture Capital firm focused on technology. His expertise includes M&A and investment analysis. He also served as innovation consultant at IIC (Inter-American Investment Corporation), a private division of the Inter-American Development Bank.

“Our choice was unanimous, taking into consideration his performance over the last three years. Furthermore, he was responsible for developing new digital solutions at Bionexo and bringing innovation into our products portfolio. Rafael also founded and led whizHealth, an initiative that promotes entrepreneurship and partnered with IFC (International Finance Corporation) to fund many innovation healthcare projects during last year through the TechEmerge program”, says Marcelo Hallack, VP of the Board of Directors and Prisma Capital partner.

“It is an honor to be named CEO by the Board of Directors. My mission has always been to significantly impact our company’s growth through innovation and products intelligence. We will get closer to the industry players, focusing on developing disruptive solutions for healthcare management in the countries we operate. Internally, we will remain loyal to the company’s DNA of valuing people and their development”, said Rafael Barbosa, Bionexo’s CEO.